INTRODUCTION
The enzyme adenosine deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4)' catalyzes the irreversible deamination of adenosine and deoxyadenosine. Special attention was drawn to this enzyme in 1972 when Giblett et al. (1) reported two young unrelated girls with severe combined immunodeficiency disease who also had absence of ADA activity in their-erythrocytes. Since that time there has been intensive probing of the relationship between ADA and immune function.
ADA deficiency causes abnormalities of deoxynucleotide and S-adenosylhomocysteine metabolism with secondary toxicity to lymphocytes and lymphoid precursors. The metabolic consequences of ADA deficiency have been thoroughly reviewed by Thompson and Seegmiller (2) and Martin and Gelfand (3) .
Less is known about the molecular basis of human ADA deficiency than about its metabolic consequences. A number of theories have been proposed to explain the loss of ADA activity in hereditary ADA deficiency. Possible explanations include (a) a mutation in the ADA structural gene (1, 4) , (b) a mutation in a gene regulating ADA expression (5) , (c) a defect in posttranslational modification of the ADA protein (6) , and (d) a chromosomal deletion in the region of the ADA gene (1) . In recent work from our laboratory (7) ADA was examined in lymphoblast cell lines established from normal and ADA-deficient individuals. ADA activity was determined by enzymatic assay and compared to ADA protein determined by two different radioimmunoassays. Using this approach, ADA-deficient cells could be divided into three types, representing at least three different mutations. It was not known whether cells were homozygous for one or heterozygous for two different mutant ADA alleles. The Carson et al. (8) and Daddona et al. (9, 10) . Their studies are also consistent with the hypothesis that several different mutations that cause ADA deficiency have occurred in humans.
Hypotheses about the molecular basis of ADA deficiency can be derived from immunological studies of ADA protein and measurements of enzymatic activity. Choosing among the hypotheses is difficult, however, because of the apparent lack of ADA protein in some mutant cells, and the small amounts of ADA protein in most other cells. This lack of ADA protein makes proof of normal or abnormal amino acid sequence difficult or impossible. Considerable additional information about these mutations and the normal synthesis of ADA 
Cell lines
The lymphoblast cell lines GM-130, GM-131, GM-2184, GM-3043, and GM-2606 are transformed B cell lines that were obtained from the Human Genetic Mutant Cell Repository (Camden, NJ). GM-130, GM-131, and GM-2184 were established from people with normal ADA activity, whereas both GM-3043 and GM-2606 are from ADA-deficient humans. The CCRF-CEM cells were obtained from the American Type Culture Collection (Rockville, MD). The HPB-ALL cells were a gift from Dr. Jun Minowada, Roswell Park Memorial Institute (Buffalo, NY). Both CCRF-CEM and HPB-ALL are leukemic lymphoblasts established from children with acute lymphoblastic leukemia and have structurally normal ADA. Cells were grown in RPMI 1640 medium supplemented with 10-20% fetal calf serum. To confirm the identity of each cell line, they were typed for surface markers using a variety of monoclonal reagents. The OKT3 and OKT4 antibodies (Ortho Diagnostic Systems, Inc., Raritan, NJ) react with certain peripheral T lymphocytes and their precursors. The BI and I2 antibodies (Coulter Electronics, Hialeah, FL) react with certain peripheral B lymphocytes and their precursors. The CCRF-CEM cells and HPB-ALL cells were verified to be T lymphoblasts (OKT3-, OKT4+, BI-, 12-and OKT3+, OKT4+, BI-, 12-, respectively). The other lines were B lymphoblasts (OKT3-, OKT4-, BI+, I2+).
Antisera
Rabbits and goats were immunized with pure homogeneous human ADA prepared from leukemic cells collected by leukophoresis (12) . The antisera to native ADA have been described and have been used extensively in radioimmunoassay of normal and mutant ADA (7) . Additional rabbit antisera were prepared against sodium dodecyl sulfate (SDS) denatured homogeneous human ADA using the immunization schedule previously described (7). All antisera gave single bands when diffused against either the antigen used for immunization or extracts of leukemic lymphoblasts.
Extraction of total RNA Total RNA was extracted from 3-10-g wet weight of late log phase cells by one of the following three methods. The concentration of RNA solutions was determined spectrophotometrically; 1 Isolation of polyadenylated mRNA Total RNA was fractionated by chromatography on oligo(dT)-cellulose (15) . The oligo(dT)-cellulose (0.5-1.0 g in a 0.7 X 10-cm column) was washed with 0.1 M KOH and then neutralized with 1 M Tris HCI, pH 7.4. Before use it was equilibrated with 50-60 ml of high salt buffer (10 mM Tris HCI, pH 7.4, 1.0 mM EDTA, 0.5 M NaCI). The RNA solution (1 mg RNA/ml in 10 mM Tris HCI, pH 7.4, 1 mM EDTA) was denatured by heating 5 min at 75°C, rapidly cooled, and then made 0.5 M in NaCl by addition of 5 M NaCl before loading on the column. Poly(A)-RNA was eluted with high salt buffer, -30 ml. The poly(A)+RNA was then eluted with 10 mM Tris HCI, pH 7.4, 1 mM EDTA.
Fractions (1 ml) containing 0.1 OD260 units or more of RNA from this low salt elution were pooled, made 0.5 M in NaCl, and chromatographed in the same manner a second time. The poly(A)+RNA from the second low salt elution was precipitated from ethanol and stored as described above for total RNA. In some cases 0.2% SDS was included in the high salt buffer and the poly(A)+RNA was eluted only once with low salt buffer. The poly(A)+RNA obtained by this latter method was quite comparable to the first in stimulation of protein synthesis in vitro and in relative content of ADA mRNA. The final yield of poly(A)+RNA was -3% of the starting RNA.
In vitro translation
In early experiments, RNA translations were performed using in vitro translation kits obtained from New England Nuclear Corporation. In later experiments lysates were prepared from reticulocyte-rich whole rabbit blood as described by Comstock et al. (16) and made mRNA dependent by treatment with 10 ug micrococcal nuclease/ml for 10 min (17) . Translation assays contained, in a total volume of 25
Ml, -50 MCi of [3S]methionine (-1,000 Ci/mmol), 0.5 ug creatine phosphokinase, 10 mM creatine phosphate, 2 mM dithiothreitol, 80 mM potassium acetate, 0.6 mM magnesium acetate, 10 Ml of lysate, and RNA. Incubations were at 37°C. Reactions were monitored by spotting aliquots on 2 X 2-cm squares of GF/C paper and immediately dropping them into cold 10% trichloroacetic acid (TCA). The squares were washed once for 10 min with cold 10% TCA, twice for 10 min each with boiling 10% TCA, and twice, for 2 min each, with ethanol. The dried squares were counted in a toluenebased scintillation cocktail using a Beckman LS 7000 counter (Beckman Instruments, Inc., Fullerton, CA). In vitro translation reactions to be used for immunoprecipitation of ADA were scaled up to 80-300 gl and were allowed to proceed for 45-55 min. After this time, 2-,ul aliquots were spotted on GF/C squares and processed as described above. The remaining in vitro translation product, i.e., the complete in vitro translation reaction mixture after incubation, was diluted with 2.5 vol of immunoprecipitation buffer containing 1 mM phenylmethylsulfonyl fluoride. The immunoprecipitation buffer was 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 M NaCl, 1 mM Na2EDTA, 1 mM methionine, and 10 mM sodium phosphate, pH 7 (18) . Following the addition of 1 Ml of nonimmune serum, the diluted in vitro translation product was incubated at 40C for 1 h. Then, 100 Ml of 10% IgGsorb in immunoprecipitation buffer was added and the mixture was incubated 15 min at room temperature. The IgGsorb and some nonspecifically bound proteins were removed by centrifugation at 15,000 g for 5 min. Anti-ADA serum, or nonimmune serum, as a control, was then added to the supernatant, and this mixture was incubated for 1 h at 4°C. The immune complex was precipitated by addition of 100 ul of 10% IgGsorb followed by a 15-min incubation at room temperature and centrifugation for 10 s at 15,000 g. The pellet was washed three times with 0.5 ml of immunoprecipitation buffer and then dissociated by a 1-h, room temperature incubation in 70 MIA of 10 mM Tris HCI, 1% SDS, 8 M urea, and 1 mM phenylmethylsulfonyl fluoride. The IgGsorb was removed by centrifugation and the dissociated, supernatant proteins were then fractionated by electrophoresis on 10% polyacrylamide, SDS-containing slab gels, 1.5 mm thick (19) . The radioactive protein bands were visualized by fluorography according to the method of Bonner and Laskey (20) . Gels were treated with En3Hance and exposed to x-ray film using an intensifying screen. Visualization required 4-18 d of exposure depending on the amount of [35S]methionine that was incorporated into the in vitro translation product.
Quantitation of ADA protein synthesized in vitro
The ADA synthesized in vitro was labeled with [35S]-methionine and therefore could be quantitated by determining the radioactivity in the gel slices that corresponded to the area to which standard ADA migrated. When wet gels were to be sliced and counted, purified ADA, 1.0 Mg, was often added to the samples of extracted immunoprecipitated protein before electrophoresis. The purified ADA was located by staining gels with Coomassie Blue. Slices were taken that corresponded to the stained ADA. Because the Coomassie Blue stain quenched fluorography, to prepare autoradiographs purified ADA was electrophoresed and stained in an adjacent lane instead of the lane containing radioactive protein. The radioactivity in ADA protein was determined by subtracting the counts in gel slices from areas with the Rf of ADA in nonimmune serum-treated in vitro translation product from the counts in the gel slices from areas containing ADA in immune serum-treated in vitro translation product. In each case an equal volume from the same in vitro translation reaction was mixed with either immune or nonimmune sera. To determine the radioactivity in the gel slices, 2-mm slices of a gel were incubated at 37°C overnight in 8 ml of 5% Protosol in a toluene-based scintillation fluid. Samples were then counted in a Beckman LS 7000 counter.
Agarose gels
Samples of RNA, 25 Ag, were denatured in 1.0 M glyoxal and fractionated on 1.5% agarose slab gels as described by McMaster and Carmichael (21) .
Assay of ADA enzymatic activity ADA activity was assayed with ['4C]adenosine as the substrate (7). Samples were assayed with and without the specific ADA inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (0.35 mM), to distinguish ADA from a second aminohydrolase that is present at low levels and not sensitive to this inhibitor. The microbiuret method was used for protein determinations (22) .
RESULTS
Isolation and in vitro translation of RNA from lymphoblast cell lines. Because lymphoblasts contain relatively high levels of ribonuclease activity (11), the procedures for isolating intact mRNA from these cells must incorporate techniques, inhibitors, and denaturing agents that minimize the activity of these degradative enzymes. The quality of a preparation of RNA can be assessed by measuring both its ability to stimulate in vitro protein synthesis and its size distribution on agarose gels. Low enous levels. Globin mRNA obtained from New England Nuclear Corporation gave three-to sixfold increases over endogenous levels of protein synthesis in the same systems. The optimal concentration of added magnesium acetate for synthesis of total protein using lymphoblast RNA and reticulocyte lysates prepared in our laboratory was 0.6 mM. The relationship between the amount of poly(A)+RNA added to a lysate and the amount of total protein synthesized was linear from 2 to -20 jig RNA/ml as shown in Fig. 1 .
Demonstration of the presence of ADA mRNA in poly(A)+RNA. Human ADA was purified by affinity chromatography to homogeneity (12) . This pure homogeneous enzyme was used to immunize animals and to compete with translation products for antibody binding sites. Three different antisera to ADA were used to immunoprecipitate newly synthesized ADA protein from the total in vitro translation products, i.e., the resultant total in vitro translation mixture following incubation at 37°C. Fluorography of 10% polyacrylamide-SDS gels containing the electrophoresed, immunoprecipitated protein revealed a band that migrated to the position of authentic human ADA, molecular weight 44,000 (Fig. 2, lane B vs. A) . This band was present in in vitro translation products immunoprecipitated with rabbit antisera raised to both native and SDS-denatured ADA and with goat antiserum to native ADA. The band was not demonstrated in in vitro translation products treated with nonimmune serum from the same rabbits that furnished the antisera against native ADA (Fig. 2) . Although the bands that migrated as authentic ADA were obvious in this gel, a number of other bands were also present. These bands represent nonimmunospecific binding, mostly The primary goal of this project was to compare in vitro translation products of ADA mRNAs from normal and ADA-deficient lymphoblast cell lines both by relative amounts and by molecular size of the ADA synthesized. If amounts of ADA synthesized in vitro by different sources of RNA are to be compared quantitatively, the amounts of antiserum used must be sufficient to precipitate the maximum amount of the relevant antigen present in the translation mixture. In the experiments shown in lanes C through J of Fig. 2 , the antiserum was limited to show competition between the newly synthesized radiolabeled ADA and the authentic unlabeled ADA. We have experimentally demonstrated that 3 y1 of our rabbit antiserum to native ADA are sufficient to bind the amount of ADA synthesized in 60 min from 4.0,g of poly(A)+RNA from HPB-ALL or CCRF-CEM cells. These two cell lines contain the highest levels of ADA catalytic activity and presumably ADA mRNA of all the lines we have studied. Using 3,l of antiserum for immunoprecipitation of in vitro translation products, the amount of ADA protein synthesized increased linearly with increased amounts of poly(A)+RNA added to the translation reactions (Fig. 1) .
Poly(A)+RNA prepared from seven different lymphoblast cell lines was translated in vitro, and the newly synthesized radiolabeled ADA was immunoprecipitated and electrophoresed on polyacrylamide-SDS gels as described in Methods. The radioactivity in ADA proteins was determined in appropriate gel slices. The amounts of total protein and ADA protein synthesized in vitro using poly(A)+RNAs from the seven cell lines are shown in Table II Most determinations of percentages of ADA synthesized were from reactions containing 20 ,ug poly(A)+RNA/ml, because up to this RNA concentration both total protein synthesis and ADA synthesis increased linearly (Fig. 1) . However, the relative amounts of ADA synthesized were also quite comparable at 40 ,ug RNA/ml (Table II) .
Relatively high levels of total protein were synthesized by in vitro translation programmed by GM-2184 poly(A)+RNA, 20 Ag/ml, but the percentage of ADA synthesized (0.0018±0.0007) was low, compared with ADA-deficient and leukemic T lines (Table II) . To determine if there might be some type of inhibitor of ADA messenger translation in these GM-2184 preparations, one in vitro translation was programmed with a one-to-one mixture of GM-2184 and CCRF-CEM poly(A)+RNA (20 ytg RNA/ml). The percentage of ADA synthesized in this reaction, 0.006, was intermediate between the ADA synthesized by the two reactions individually. Therefore, there was no specific inhibitor of translation of ADA mRNA in the GM-2184 poly(A)+ preparation. To determine whether the low relative content of ADA-specific mRNA was unique to the GM-2184 cell line, two additional normal B lines were studied. Both GM-130 and GM-131 were similar to GM-2184 in relative ADA mRNA content, so the property is not unique (Table I1) .
The size of ADA proteins was determined by comparison of migrations of the immunoprecipitated newly synthesized ADA with migration of authentic human ADA (12) and other standard proteins on polyacrylamide-SDS gels. The poly(A)+RNAs from all mRNA in Adenosine Deaminase Deficiency 20 Mg poly(A) RNA/ml. Catalytic activities were by measurement of ADA activity in extracts of the same batch of cells used to prepare RNA except for HPB-ALL cells where the original cells were not assayed and a second batch was tested. ADA activity in GM-2184 was 53 nmol inosine/min per mg protein. Immunoreactive ADA protein was measured by radioimmunoassay using goat antiserum to human ADA (GM-2184, GM-2606, CCRF-CEM, HPB-ALL) or rabbit antiserum to human ADA (GM-2184, GM-3043) (see reference 7 for a discussion of the properties of these sera when used to assay mutant proteins). The values reported for GM-3043 and GM-2606 represent the greatest amount of protein detected by any type of radioimmunoassay. GM-2184 cells contained 645±161 (n = 5) ng/108 cells using goat antiserum and 800 ng/10' cells using rabbit antiserum. Catalytic activities and imtnunoreactive protein were not measured in the same batches of cells. § Number of separate determinations that were averaged is shown in parentheses. The ratio, ADA/total, for CCRF-CEM, GM-2184, and GM-2606 shows the mean±SD. Values for GM-2184 and CCRF-CEM each include determinations made on RNAs isolated from two batches of cells.
seven of the lymphoblast cell lines yielded ADA proteins that were either equal to or very close to the same size as normal human ADA as shown by their comigration with authentic ADA (Fig. 3) . Our sizing gel could resolve differences in molecular weight of 1,000 or less. This is equivalent to -10 amino acids in the protein or 30 base pairs in the structural gene. The ADA from the normal B lines, GM-130, GM-131, and GM-2184, was more difficult to visualize than ADA from other cell lines because of the relatively low amount of ADA-specific mRNA in these lines (Table II) .
Comparisons of the ADA catalytic activity in extracts of cells grown in culture with the amount of ADA protein in extracts by radioimmunoassay and amounts of mRNA by in vitro translation are shown in columns 5, 6, and 7, Table II . The catalytic activity found in GM-3043 cells was higher than previously found in our laboratory (7) and by others (23) . The activity of ADA that is detected in this cell line varies considerably from preparation to preparation of cells in bulk, probably because of thermolability of the mutant protein (23) . This property was maintained by the GM-3043 cells in culture in our laboratory. Heating at 54°C for 20 min resulted in loss of 96% of the ADA catalytic activity in extracts from GM-3043 cells to be compared with 48% loss of activity in extracts from GM-2184 cells.
DISCUSSION
ADA activity is deficient in the most common form of hereditary severe combined immunodeficiency disease (1-3) . However, the molecular basis of ADA deficiency is not well understood. Evidence of mutations in the structural gene for ADA has been gained by determining the ratios of ADA protein to catalytic activity in cells and cell lines from people with ADA deficiency (7) (8) (9) (10) and by demonstrating ADA proteins with decreased heat stability in cells from some patients with hereditary ADA deficiency (23 (27) . The second ADA-deficient cell line, GM-2606, was derived from lymphocytes of an 8-mo-old immunodeficient boy (26) . These cells contain very low levels of enzyme activity and protein.
RNA was isolated from the seven different lymphoblast cell lines and poly(A)+RNA was prepared from the total RNA of each line. Autoradiographs of polyacrylamide-SDS gels of electrophoresed, immunoprecipitated in vitro translation products from the poly(A)+RNA preparations of all seven cell lines revealed that ADA had been synthesized. Therefore, all of the poly(A)+RNA preparations contained ADA mRNA. Verification of the synthesis of ADA was obtained through demonstration of (a) specific immunoprecipitation of newly synthesized protein using three different antisera, one rabbit antiserum directed against native human ADA, one rabbit antiserum directed against SDS-denatured ADA, and one goat antiserum against native human ADA; (b) comigration of bands of newly synthesized protein with authentic ADA when immunoprecipitated translation products were electrophoresed on SDS-gels; and (c) competition between the newly synthesized radioactive ADA and purified homogeneous nonradioactive human ADA for antibody binding sites. Competition between purified authentic ADA and newly synthesized ADA was demonstrated for translation products of mRNAs from four different cell lines (Fig. 2 23 and Results). Such an amino acid substitution could induce a conformational change in the molecule that would lead to more rapid denaturation and degradation. The amount of radioactivity incorporated into the translation products is inadequate to permit direct structural analysis by autoradiographs of peptide maps.
The relative amounts of a specific protein synthesized in vitro have frequently been used to estimate relative amounts of specific mRNAs, or more accurately, specific translatable mRNAs in poly(A)+RNA preparations (15, (28) (29) (30) The relative amounts of translatable ADA mRNA in the two mutant, ADA-deficient cell lines were three to fourfold greater than in the normal B cell lines and half that of the T lymphoblast lines (Table II, column  5) . When compared with in vivo steady-state levels of the mutant ADA proteins, the relative amounts of ADA protein synthesized by in vitro translation were from three-to 33-fold more than the greatest relative amounts of ADA protein that we have detected in cell extracts by radioimmunoassay (Table II columns 5 and  7) . However, in the caes of the cell derived from the !Kung child, the GM-3043 line, an occasional catalytic and radioimmunoassay has revealed more ADA activity and protein than found in the normal B cell lines. That the level of translatable ADA mRNA would be higher than the relative amount of ADA protein in GM-3043 cells was not entirely unexpected because of the evidence that the cells could make a thermolabile ADA in substantial quantities. That the ADA specific mRNA in GM-3043 would be three-fold higher than ADA specific mRNA in normal B lymphoblasts was unexpected. The finding of levels of translatable ADA mRNA in the GM-2606 cells that were three-fold greater than in the normal B cell lines was entirely unexpected because the most ADA protein that had been detected in extracts of these cells was only onetenth that of the normal B cell lines (reference 7 and Table II ). The relative amounts of translatable ADA mRNA and actual percentages of ADA synthesized in vitro in the two mutant cell lines indicate that the deficient levels of ADA protein found in these cells in vivo are not caused by deficient mRNA levels; in fact, three-fold greater than normal levels of ADA mRNA appear to be present. The deficient levels of ADA protein in cell extracts in the presence of increased mRNA and increased rate of synthesis could be explained if defective mutant proteins are made that are abnormally unstable and rapidly degraded. The finding of an increased rate of enzyme synthesis associated with a structural mutation would not be unprecedented. In 1970, Yoshida (32) reported that a single amino acid substitution, histidine to tyrosine, in human glucose-6-phosphate dehydrogenase was associated with a fourfold increase in concentration and rate of synthesis of the protein in cells. Whether the increased synthesis was secondary to increased amounts of mRNA in cells or to an increased efficiency of translation was not determined. Apparently the mutant glucose-6-phosphate dehydrogenase was as stable as the normal enzyme in contrast to the two ADA mutant proteins we have studied. Melton et al. (33) demonstrated a 25-to 50-fold overproduction of hypoxanthine/guanine phosphoribosyl-transferase in in vitro translations of poly(A)+ RNA from a mouse neuroblastoma revertant cell line. This overproduced enzyme was also structurally defective as indicated by greatly reduced thermal stability relative to the wild type mouse enzyme.
The variation in translatable ADA mRNA in our seven lymphoblast cell lines may be caused by actual differences in mRNA levels or by different efficiencies of translation of similar amounts of mRNA. However, studies of CAD enzyme (a multifunctional protein containing carbamyl-P-synthetase, aspartate transcarbamylase, and dihydroorotase activities) (34) and dihydrofolate reductase (35) have shown a close correlation between levels of enzyme protein and specific mRNA in a variety of cell types. Whether this correlation exists for ADA in normal and mutant cell lines remains to be shown. If the amounts of adenosine deaminase mRNA are actually increased in the mutant B lines and leukemic T lines over the normal B lines, the question of the mechanisms of this increase in specific messenger arises. It could be caused by more efficient
